PDF(Pubmed)
Abstract：
As indications for immune checkpoint inhibitors for breast cancer continue to expand, rare toxicities will emerge that require careful consideration and multidisciplinary management. We report the case of a 40-year-old female receiving neoadjuvant pembrolizumab and chemotherapy for locally advanced triple-negative breast cancer who developed cytokine release syndrome (CRS)/hemophagocytic lymphohistiocytosis (HLH). CRS/HLH secondary to pembrolizumab are scarcely documented in the literature and, to our knowledge, have never been reported in the context of neoadjuvant treatment for breast cancer.
摘要：
随着乳腺癌免疫检查点抑制剂的适应症不断扩大，罕见的毒性将出现，需要仔细考虑和多学科管理。我们报告了一名40岁女性，接受新辅助派姆单抗和化疗治疗局部晚期三阴性乳腺癌的情况，该患者出现了细胞因子释放综合征（CRS）/噬血细胞淋巴组织细胞增多症（HLH）。pembrolizumab继发的CRS/HLH在文献中几乎没有记载，根据我们的知识，从未在乳腺癌新辅助治疗的背景下报道过。
